Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Muzastotug (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Liver metastases; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Adagene

    • Most Recent Events

    • 09 Oct 2024 According to an Adagene media release, company will present data from this study at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov 9, 2024.
    • 17 Sep 2024 According to an Adagene media release, Initial data for this cohort are expected later this year.
    • 16 Sep 2024 According to an Adagene media release, data from this study were presented at the ESMO Congress, taking place in Barcelona, Spain, September 13-17.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top